ACLX - Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today? | Benzinga
Arcellx Inc (NASDAQ: ACLX) announced that new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma will be presented at the 65th American Society of Hematology (ASH).
The data in the ASH abstract published today is from a June 2, 2023 data cut and will include new data with a median follow-up of 26.5 months.
As detailed in the abstract, 38 patients were evaluable for efficacy and safety analysis, based on a median follow-up of 22 months following treatment.
Related: Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential.
These evaluable patients comprised the dose escalation cohorts for the first ...